Endocan Levels and Endothelial Dysfunction in Patients With Sarcoidosis
Angiology, cilt.69, sa.10, ss.878-883, 2018 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 69 Sayı: 10
- Basım Tarihi: 2018
- Doi Numarası: 10.1177/0003319718775283
- Dergi Adı: Angiology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.878-883
- Anahtar Kelimeler: endocan, sarcoidosis, endothelial dysfunction, atherosclerosis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
A systemic inflammatory reaction is a common feature of both sarcoidosis and atherosclerosis. Endothelial-cell specific molecule 1 (endocan) is a marker of vascular pathology which also shows a correlation with inflammation, endothelial dysfunction, and atherosclerosis. The objective of this study was to evaluate the vascular involvement in sarcoidosis using serum endocan levels and brachial artery flow–mediated dilation (FMD), a marker of endothelial dysfunction. We included 53 patients with sarcoidosis without conventional cardiovascular risk factors and 40 healthy controls. Endothelial function was assessed using FMD. Endocan concentrations were measured using a commercially available enzyme-linked immunoassay. Patients with sarcoidosis had significantly higher endocan levels (306 [68] ng/mL vs 269 [73] ng/mL; P =.039) and lower FMD (2.7% [2.3%-3.2%] vs 8% [5%-13%]; P <.001) compared with the healthy group. A negative correlation was found between endocan levels and FMD in the sarcoidosis group (r = −.325, P <.007). We conclude that sarcoidosis is associated with high levels of endocan and lower FMD values, which may indicate endothelial dysfunction and an early stage of atherosclerosis.